VCV000091636.48 - ClinVar

NM_007294.4(BRCA1):c.5074+6C>G

Germline

Top reviewed classifications are shown here.

Submission summary:

25 submissions

25 submitters

6 conditions

Reviewed by expert panel

Benign

Jun 2019 by Evidence-based…

for Breast-ovarian cancer, familial, susceptibility to, 1

Somatic

No data submitted for somatic clinical impact

Somatic

No data submitted for oncogenicity

Variant Details

Identifiers

NM_007294.4(BRCA1):c.5074+6C>G

Variation ID: 91636 Accession: VCV000091636.48

Type and length

single nucleotide variant, 1 bp

Location

Cytogenetic: 17q21.31 17: 43067602 (GRCh38) [ NCBI UCSC ] 17: 41219619 (GRCh37) [ NCBI UCSC ]

Timeline in ClinVar

	First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.	Last submission Help The date of the most recent submission for each type of classification for this variant.	Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline	Apr 1, 2014	Oct 20, 2024	Jun 18, 2019

HGVS

Nucleotide	Protein	Molecular consequence
NM_007294.4:c.5074+6C>G MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.		intron variant
NM_001407571.1:c.4861+6C>G		intron variant
NM_001407581.1:c.5140+6C>G		intron variant
NM_001407582.1:c.5140+6C>G		intron variant
NM_001407583.1:c.5137+6C>G		intron variant
NM_001407585.1:c.5137+6C>G		intron variant
NM_001407587.1:c.5137+6C>G		intron variant
NM_001407590.1:c.5134+6C>G		intron variant
NM_001407591.1:c.5134+6C>G		intron variant
NM_001407593.1:c.5074+6C>G		intron variant
NM_001407594.1:c.5074+6C>G		intron variant
NM_001407596.1:c.5074+6C>G		intron variant
NM_001407597.1:c.5074+6C>G		intron variant
NM_001407598.1:c.5074+6C>G		intron variant
NM_001407602.1:c.5074+6C>G		intron variant
NM_001407603.1:c.5074+6C>G		intron variant
NM_001407605.1:c.5074+6C>G		intron variant
NM_001407610.1:c.5071+6C>G		intron variant
NM_001407611.1:c.5071+6C>G		intron variant
NM_001407612.1:c.5071+6C>G		intron variant
NM_001407613.1:c.5071+6C>G		intron variant
NM_001407614.1:c.5071+6C>G		intron variant
NM_001407615.1:c.5071+6C>G		intron variant
NM_001407616.1:c.5071+6C>G		intron variant
NM_001407617.1:c.5071+6C>G		intron variant
NM_001407618.1:c.5071+6C>G		intron variant
NM_001407619.1:c.5071+6C>G		intron variant
NM_001407620.1:c.5071+6C>G		intron variant
NM_001407621.1:c.5071+6C>G		intron variant
NM_001407622.1:c.5071+6C>G		intron variant
NM_001407623.1:c.5071+6C>G		intron variant
NM_001407624.1:c.5071+6C>G		intron variant
NM_001407625.1:c.5071+6C>G		intron variant
NM_001407626.1:c.5071+6C>G		intron variant
NM_001407627.1:c.5068+6C>G		intron variant
NM_001407628.1:c.5068+6C>G		intron variant
NM_001407629.1:c.5068+6C>G		intron variant
NM_001407630.1:c.5068+6C>G		intron variant
NM_001407631.1:c.5068+6C>G		intron variant
NM_001407632.1:c.5068+6C>G		intron variant
NM_001407633.1:c.5068+6C>G		intron variant
NM_001407634.1:c.5068+6C>G		intron variant
NM_001407635.1:c.5068+6C>G		intron variant
NM_001407636.1:c.5068+6C>G		intron variant
NM_001407637.1:c.5068+6C>G		intron variant
NM_001407638.1:c.5068+6C>G		intron variant
NM_001407639.1:c.5068+6C>G		intron variant
NM_001407640.1:c.5068+6C>G		intron variant
NM_001407641.1:c.5068+6C>G		intron variant
NM_001407642.1:c.5068+6C>G		intron variant
NM_001407644.1:c.5065+6C>G		intron variant
NM_001407645.1:c.5065+6C>G		intron variant
NM_001407646.1:c.5062+6C>G		intron variant
NM_001407647.1:c.5059+6C>G		intron variant
NM_001407648.1:c.5017+6C>G		intron variant
NM_001407649.1:c.5014+6C>G		intron variant
NM_001407652.1:c.5074+6C>G		intron variant
NM_001407653.1:c.4996+6C>G		intron variant
NM_001407654.1:c.4996+6C>G		intron variant
NM_001407655.1:c.4996+6C>G		intron variant
NM_001407656.1:c.4993+6C>G		intron variant
NM_001407657.1:c.4993+6C>G		intron variant
NM_001407658.1:c.4993+6C>G		intron variant
NM_001407659.1:c.4990+6C>G		intron variant
NM_001407660.1:c.4990+6C>G		intron variant
NM_001407661.1:c.4990+6C>G		intron variant
NM_001407662.1:c.4990+6C>G		intron variant
NM_001407663.1:c.4990+6C>G		intron variant
NM_001407664.1:c.4951+6C>G		intron variant
NM_001407665.1:c.4951+6C>G		intron variant
NM_001407666.1:c.4951+6C>G		intron variant
NM_001407667.1:c.4951+6C>G		intron variant
NM_001407668.1:c.4951+6C>G		intron variant
NM_001407669.1:c.4951+6C>G		intron variant
NM_001407670.1:c.4948+6C>G		intron variant
NM_001407671.1:c.4948+6C>G		intron variant
NM_001407672.1:c.4948+6C>G		intron variant
NM_001407673.1:c.4948+6C>G		intron variant
NM_001407674.1:c.4948+6C>G		intron variant
NM_001407675.1:c.4948+6C>G		intron variant
NM_001407676.1:c.4948+6C>G		intron variant
NM_001407677.1:c.4948+6C>G		intron variant
NM_001407678.1:c.4948+6C>G		intron variant
NM_001407679.1:c.4948+6C>G		intron variant
NM_001407680.1:c.4948+6C>G		intron variant
NM_001407681.1:c.4945+6C>G		intron variant
NM_001407682.1:c.4945+6C>G		intron variant
NM_001407683.1:c.4945+6C>G		intron variant
NM_001407684.1:c.5074+6C>G		intron variant
NM_001407685.1:c.4945+6C>G		intron variant
NM_001407686.1:c.4945+6C>G		intron variant
NM_001407687.1:c.4945+6C>G		intron variant
NM_001407688.1:c.4945+6C>G		intron variant
NM_001407689.1:c.4945+6C>G		intron variant
NM_001407690.1:c.4942+6C>G		intron variant
NM_001407691.1:c.4942+6C>G		intron variant
NM_001407692.1:c.4933+6C>G		intron variant
NM_001407694.1:c.4933+6C>G		intron variant
NM_001407695.1:c.4933+6C>G		intron variant
NM_001407696.1:c.4933+6C>G		intron variant
NM_001407697.1:c.4933+6C>G		intron variant
NM_001407698.1:c.4933+6C>G		intron variant
NM_001407724.1:c.4933+6C>G		intron variant
NM_001407725.1:c.4933+6C>G		intron variant
NM_001407726.1:c.4933+6C>G		intron variant
NM_001407727.1:c.4933+6C>G		intron variant
NM_001407728.1:c.4933+6C>G		intron variant
NM_001407729.1:c.4933+6C>G		intron variant
NM_001407730.1:c.4933+6C>G		intron variant
NM_001407731.1:c.4933+6C>G		intron variant
NM_001407732.1:c.4930+6C>G		intron variant
NM_001407733.1:c.4930+6C>G		intron variant
NM_001407734.1:c.4930+6C>G		intron variant
NM_001407735.1:c.4930+6C>G		intron variant
NM_001407736.1:c.4930+6C>G		intron variant
NM_001407737.1:c.4930+6C>G		intron variant
NM_001407738.1:c.4930+6C>G		intron variant
NM_001407739.1:c.4930+6C>G		intron variant
NM_001407740.1:c.4930+6C>G		intron variant
NM_001407741.1:c.4930+6C>G		intron variant
NM_001407742.1:c.4930+6C>G		intron variant
NM_001407743.1:c.4930+6C>G		intron variant
NM_001407744.1:c.4930+6C>G		intron variant
NM_001407745.1:c.4930+6C>G		intron variant
NM_001407746.1:c.4930+6C>G		intron variant
NM_001407747.1:c.4930+6C>G		intron variant
NM_001407748.1:c.4930+6C>G		intron variant
NM_001407749.1:c.4930+6C>G		intron variant
NM_001407750.1:c.4930+6C>G		intron variant
NM_001407751.1:c.4930+6C>G		intron variant
NM_001407752.1:c.4930+6C>G		intron variant
NM_001407838.1:c.4927+6C>G		intron variant
NM_001407839.1:c.4927+6C>G		intron variant
NM_001407841.1:c.4927+6C>G		intron variant
NM_001407842.1:c.4927+6C>G		intron variant
NM_001407843.1:c.4927+6C>G		intron variant
NM_001407844.1:c.4927+6C>G		intron variant
NM_001407845.1:c.4927+6C>G		intron variant
NM_001407846.1:c.4927+6C>G		intron variant
NM_001407847.1:c.4927+6C>G		intron variant
NM_001407848.1:c.4927+6C>G		intron variant
NM_001407849.1:c.4927+6C>G		intron variant
NM_001407850.1:c.4927+6C>G		intron variant
NM_001407851.1:c.4927+6C>G		intron variant
NM_001407852.1:c.4927+6C>G		intron variant
NM_001407853.1:c.4927+6C>G		intron variant
NM_001407854.1:c.5074+6C>G		intron variant
NM_001407858.1:c.5071+6C>G		intron variant
NM_001407859.1:c.5071+6C>G		intron variant
NM_001407860.1:c.5071+6C>G		intron variant
NM_001407861.1:c.5068+6C>G		intron variant
NM_001407862.1:c.4873+6C>G		intron variant
NM_001407863.1:c.4948+6C>G		intron variant
NM_001407874.1:c.4867+6C>G		intron variant
NM_001407875.1:c.4867+6C>G		intron variant
NM_001407879.1:c.4864+6C>G		intron variant
NM_001407881.1:c.4864+6C>G		intron variant
NM_001407882.1:c.4864+6C>G		intron variant
NM_001407884.1:c.4864+6C>G		intron variant
NM_001407885.1:c.4864+6C>G		intron variant
NM_001407886.1:c.4864+6C>G		intron variant
NM_001407887.1:c.4864+6C>G		intron variant
NM_001407889.1:c.4864+6C>G		intron variant
NM_001407894.1:c.4861+6C>G		intron variant
NM_001407895.1:c.4861+6C>G		intron variant
NM_001407896.1:c.4861+6C>G		intron variant
NM_001407897.1:c.4861+6C>G		intron variant
NM_001407898.1:c.4861+6C>G		intron variant
NM_001407899.1:c.4861+6C>G		intron variant
NM_001407900.1:c.4861+6C>G		intron variant
NM_001407902.1:c.4861+6C>G		intron variant
NM_001407904.1:c.4861+6C>G		intron variant
NM_001407906.1:c.4861+6C>G		intron variant
NM_001407907.1:c.4861+6C>G		intron variant
NM_001407908.1:c.4861+6C>G		intron variant
NM_001407909.1:c.4861+6C>G		intron variant
NM_001407910.1:c.4861+6C>G		intron variant
NM_001407915.1:c.4858+6C>G		intron variant
NM_001407916.1:c.4858+6C>G		intron variant
NM_001407917.1:c.4858+6C>G		intron variant
NM_001407918.1:c.4858+6C>G		intron variant
NM_001407919.1:c.4951+6C>G		intron variant
NM_001407920.1:c.4810+6C>G		intron variant
NM_001407921.1:c.4810+6C>G		intron variant
NM_001407922.1:c.4810+6C>G		intron variant
NM_001407923.1:c.4810+6C>G		intron variant
NM_001407924.1:c.4810+6C>G		intron variant
NM_001407925.1:c.4810+6C>G		intron variant
NM_001407926.1:c.4810+6C>G		intron variant
NM_001407927.1:c.4807+6C>G		intron variant
NM_001407928.1:c.4807+6C>G		intron variant
NM_001407929.1:c.4807+6C>G		intron variant
NM_001407930.1:c.4807+6C>G		intron variant
NM_001407931.1:c.4807+6C>G		intron variant
NM_001407932.1:c.4807+6C>G		intron variant
NM_001407933.1:c.4807+6C>G		intron variant
NM_001407934.1:c.4804+6C>G		intron variant
NM_001407935.1:c.4804+6C>G		intron variant
NM_001407936.1:c.4804+6C>G		intron variant
NM_001407937.1:c.4951+6C>G		intron variant
NM_001407938.1:c.4951+6C>G		intron variant
NM_001407939.1:c.4948+6C>G		intron variant
NM_001407940.1:c.4948+6C>G		intron variant
NM_001407941.1:c.4945+6C>G		intron variant
NM_001407942.1:c.4933+6C>G		intron variant
NM_001407943.1:c.4930+6C>G		intron variant
NM_001407944.1:c.4930+6C>G		intron variant
NM_001407945.1:c.4930+6C>G		intron variant
NM_001407946.1:c.4741+6C>G		intron variant
NM_001407947.1:c.4741+6C>G		intron variant
NM_001407948.1:c.4741+6C>G		intron variant
NM_001407949.1:c.4741+6C>G		intron variant
NM_001407950.1:c.4738+6C>G		intron variant
NM_001407951.1:c.4738+6C>G		intron variant
NM_001407952.1:c.4738+6C>G		intron variant
NM_001407953.1:c.4738+6C>G		intron variant
NM_001407954.1:c.4738+6C>G		intron variant
NM_001407955.1:c.4738+6C>G		intron variant
NM_001407956.1:c.4735+6C>G		intron variant
NM_001407957.1:c.4735+6C>G		intron variant
NM_001407958.1:c.4735+6C>G		intron variant
NM_001407959.1:c.4693+6C>G		intron variant
NM_001407960.1:c.4690+6C>G		intron variant
NM_001407962.1:c.4690+6C>G		intron variant
NM_001407963.1:c.4687+6C>G		intron variant
NM_001407964.1:c.4612+6C>G		intron variant
NM_001407965.1:c.4567+6C>G		intron variant
NM_001407966.1:c.4186+6C>G		intron variant
NM_001407967.1:c.4183+6C>G		intron variant
NM_001407968.1:c.2470+6C>G		intron variant
NM_001407969.1:c.2467+6C>G		intron variant
NM_001407970.1:c.1831+6C>G		intron variant
NM_001407971.1:c.1831+6C>G		intron variant
NM_001407972.1:c.1828+6C>G		intron variant
NM_001407973.1:c.1765+6C>G		intron variant
NM_001407974.1:c.1765+6C>G		intron variant
NM_001407975.1:c.1765+6C>G		intron variant
NM_001407976.1:c.1765+6C>G		intron variant
NM_001407977.1:c.1765+6C>G		intron variant
NM_001407978.1:c.1765+6C>G		intron variant
NM_001407979.1:c.1762+6C>G		intron variant
NM_001407980.1:c.1762+6C>G		intron variant
NM_001407981.1:c.1762+6C>G		intron variant
NM_001407982.1:c.1762+6C>G		intron variant
NM_001407983.1:c.1762+6C>G		intron variant
NM_001407984.1:c.1762+6C>G		intron variant
NM_001407985.1:c.1762+6C>G		intron variant
NM_001407986.1:c.1762+6C>G		intron variant
NM_001407990.1:c.1762+6C>G		intron variant
NM_001407991.1:c.1762+6C>G		intron variant
NM_001407992.1:c.1762+6C>G		intron variant
NM_001407993.1:c.1762+6C>G		intron variant
NM_001408392.1:c.1759+6C>G		intron variant
NM_001408396.1:c.1759+6C>G		intron variant
NM_001408397.1:c.1759+6C>G		intron variant
NM_001408398.1:c.1759+6C>G		intron variant
NM_001408399.1:c.1759+6C>G		intron variant
NM_001408400.1:c.1759+6C>G		intron variant
NM_001408401.1:c.1759+6C>G		intron variant
NM_001408402.1:c.1759+6C>G		intron variant
NM_001408403.1:c.1759+6C>G		intron variant
NM_001408404.1:c.1759+6C>G		intron variant
NM_001408406.1:c.1756+6C>G		intron variant
NM_001408407.1:c.1756+6C>G		intron variant
NM_001408408.1:c.1756+6C>G		intron variant
NM_001408409.1:c.1753+6C>G		intron variant
NM_001408410.1:c.1690+6C>G		intron variant
NM_001408411.1:c.1687+6C>G		intron variant
NM_001408412.1:c.1684+6C>G		intron variant
NM_001408413.1:c.1684+6C>G		intron variant
NM_001408414.1:c.1684+6C>G		intron variant
NM_001408415.1:c.1684+6C>G		intron variant
NM_001408416.1:c.1684+6C>G		intron variant
NM_001408418.1:c.1648+6C>G		intron variant
NM_001408419.1:c.1648+6C>G		intron variant
NM_001408420.1:c.1648+6C>G		intron variant
NM_001408421.1:c.1645+6C>G		intron variant
NM_001408422.1:c.1645+6C>G		intron variant
NM_001408423.1:c.1645+6C>G		intron variant
NM_001408424.1:c.1645+6C>G		intron variant
NM_001408425.1:c.1642+6C>G		intron variant
NM_001408426.1:c.1642+6C>G		intron variant
NM_001408427.1:c.1642+6C>G		intron variant
NM_001408428.1:c.1642+6C>G		intron variant
NM_001408429.1:c.1642+6C>G		intron variant
NM_001408430.1:c.1642+6C>G		intron variant
NM_001408431.1:c.1642+6C>G		intron variant
NM_001408432.1:c.1639+6C>G		intron variant
NM_001408433.1:c.1639+6C>G		intron variant
NM_001408434.1:c.1639+6C>G		intron variant
NM_001408435.1:c.1639+6C>G		intron variant
NM_001408436.1:c.1639+6C>G		intron variant
NM_001408437.1:c.1639+6C>G		intron variant
NM_001408438.1:c.1639+6C>G		intron variant
NM_001408439.1:c.1639+6C>G		intron variant
NM_001408440.1:c.1639+6C>G		intron variant
NM_001408441.1:c.1639+6C>G		intron variant
NM_001408442.1:c.1639+6C>G		intron variant
NM_001408443.1:c.1639+6C>G		intron variant
NM_001408444.1:c.1639+6C>G		intron variant
NM_001408445.1:c.1636+6C>G		intron variant
NM_001408446.1:c.1636+6C>G		intron variant
NM_001408447.1:c.1636+6C>G		intron variant
NM_001408448.1:c.1636+6C>G		intron variant
NM_001408450.1:c.1636+6C>G		intron variant
NM_001408451.1:c.1630+6C>G		intron variant
NM_001408452.1:c.1624+6C>G		intron variant
NM_001408453.1:c.1624+6C>G		intron variant
NM_001408454.1:c.1624+6C>G		intron variant
NM_001408455.1:c.1624+6C>G		intron variant
NM_001408456.1:c.1624+6C>G		intron variant
NM_001408457.1:c.1624+6C>G		intron variant
NM_001408458.1:c.1621+6C>G		intron variant
NM_001408459.1:c.1621+6C>G		intron variant
NM_001408460.1:c.1621+6C>G		intron variant
NM_001408461.1:c.1621+6C>G		intron variant
NM_001408462.1:c.1621+6C>G		intron variant
NM_001408463.1:c.1621+6C>G		intron variant
NM_001408464.1:c.1621+6C>G		intron variant
NM_001408465.1:c.1621+6C>G		intron variant
NM_001408466.1:c.1621+6C>G		intron variant
NM_001408467.1:c.1621+6C>G		intron variant
NM_001408468.1:c.1618+6C>G		intron variant
NM_001408469.1:c.1618+6C>G		intron variant
NM_001408470.1:c.1618+6C>G		intron variant
NM_001408472.1:c.1762+6C>G		intron variant
NM_001408473.1:c.1759+6C>G		intron variant
NM_001408474.1:c.1564+6C>G		intron variant
NM_001408475.1:c.1561+6C>G		intron variant
NM_001408476.1:c.1561+6C>G		intron variant
NM_001408478.1:c.1555+6C>G		intron variant
NM_001408479.1:c.1555+6C>G		intron variant
NM_001408480.1:c.1555+6C>G		intron variant
NM_001408481.1:c.1552+6C>G		intron variant
NM_001408482.1:c.1552+6C>G		intron variant
NM_001408483.1:c.1552+6C>G		intron variant
NM_001408484.1:c.1552+6C>G		intron variant
NM_001408485.1:c.1552+6C>G		intron variant
NM_001408489.1:c.1552+6C>G		intron variant
NM_001408490.1:c.1552+6C>G		intron variant
NM_001408491.1:c.1552+6C>G		intron variant
NM_001408492.1:c.1549+6C>G		intron variant
NM_001408493.1:c.1549+6C>G		intron variant
NM_001408494.1:c.1525+6C>G		intron variant
NM_001408495.1:c.1519+6C>G		intron variant
NM_001408496.1:c.1501+6C>G		intron variant
NM_001408497.1:c.1501+6C>G		intron variant
NM_001408498.1:c.1501+6C>G		intron variant
NM_001408499.1:c.1501+6C>G		intron variant
NM_001408500.1:c.1501+6C>G		intron variant
NM_001408501.1:c.1501+6C>G		intron variant
NM_001408502.1:c.1498+6C>G		intron variant
NM_001408503.1:c.1498+6C>G		intron variant
NM_001408504.1:c.1498+6C>G		intron variant
NM_001408505.1:c.1495+6C>G		intron variant
NM_001408506.1:c.1438+6C>G		intron variant
NM_001408507.1:c.1435+6C>G		intron variant
NM_001408508.1:c.1426+6C>G		intron variant
NM_001408509.1:c.1423+6C>G		intron variant
NM_001408510.1:c.1384+6C>G		intron variant
NM_001408511.1:c.1381+6C>G		intron variant
NM_001408512.1:c.1261+6C>G		intron variant
NM_001408513.1:c.1234+6C>G		intron variant
NM_001408514.1:c.839-3651C>G		intron variant
NM_007297.4:c.4933+6C>G		intron variant
NM_007298.4:c.1762+6C>G		intron variant
NM_007299.4:c.1762+6C>G		intron variant
NM_007300.4:c.5137+6C>G		intron variant
NC_000017.11:g.43067602G>C
NC_000017.10:g.41219619G>C
NG_005905.2:g.150382C>G
LRG_292:g.150382C>G
LRG_292t1:c.5074+6C>G
U14680.1:n.5193+6C>G

... more HGVS ... less HGVS

Protein change

Other names

IVS17+6C>G

Canonical SPDI

NC_000017.11:43067601:G:C

Functional consequence Help The effect of the variant on RNA or protein function, based on experimental evidence from submitters.

functionally_normal; Sequence Ontology [ SO:0002219]

The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5074+6C>G, a SPLICE REGION variant, produced a function score of -0.36, corresponding to a functional classification of FUNCTIONAL. SGE function score ranges for classification are as follows: â€˜functionalâ€™, score > -0.748; â€˜intermediateâ€™, -0.748 > score > -1.328; â€˜non-functionalâ€™, score < -1.328. The median synonymous SNV scored 0.0 and the median nonsense SNV scored -2.12. [submitted by Brotman Baty Institute, University of Washington]

Global minor allele frequency (GMAF) Help The global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.

Allele frequency Help The frequency of the allele represented by this VCV record.

The Genome Aggregation Database (gnomAD) 0.00002

Exome Aggregation Consortium (ExAC) 0.00006

The Genome Aggregation Database (gnomAD), exomes 0.00006

Trans-Omics for Precision Medicine (TOPMed) 0.00007

NHLBI Exome Sequencing Project (ESP) Exome Variant Server 0.00008

Links

Breast Cancer Information Core (BIC) (BRCA1): 5193+6&base_change=C to G ClinGen: CA003200 dbSNP: rs80358032 VarSome

Genes

Gene	OMIM	ClinGen Gene Dosage Sensitivity Curation		Variation Viewer Help Links to Variation Viewer, a genome browser to view variation data from NCBI databases.	Related variants
Gene	OMIM	HI score Help The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.	TS score Help The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.		Within gene Help The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants.	All Help The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene.
BRCA1		Sufficient evidence for dosage pathogenicity	No evidence available	GRCh38 GRCh37	13040	14846

Conditions - Germline

Condition Help The condition for this variant-condition (RCV) record in ClinVar.	Classification Help The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions)	Review status Help The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status.	Last evaluated Help The most recent date that a submitter evaluated this variant for the condition.	Variation/condition record Help The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page.
Breast-ovarian cancer, familial, susceptibility to, 1	Benign (9)	reviewed by expert panel	Jun 18, 2019	RCV000077153.25
Hereditary breast ovarian cancer syndrome	Benign (2)	criteria provided, single submitter	Jan 4, 2024	RCV000205845.26
Hereditary cancer-predisposing syndrome	Likely benign (2)	criteria provided, multiple submitters, no conflicts	Sep 15, 2021	RCV000447045.10
not specified	Benign (5)	criteria provided, multiple submitters, no conflicts	Aug 15, 2023	RCV000501126.22
not provided	Benign/Likely benign (6)	criteria provided, multiple submitters, no conflicts	Mar 1, 2024	RCV000656627.28
Breast and/or ovarian cancer	Likely benign (1)	no assertion criteria provided	Oct 7, 2013	RCV000735560.9

Submissions - Germline

Classification Help The submitted germline classification for each SCV record. (Last evaluated)	Review status Help Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria)	Condition Help The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant.	Submitter Help The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar.	More information Help This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter.
Benign (Jun 18, 2019)	reviewed by expert panel (ENIGMA BRCA1/2 Classification Criteria (2017-06-29)) Method: curation	Breast-ovarian cancer, familial, susceptibility to, 1 Affected status: unknown Allele origin: germline	Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Accession: SCV001161602.2 First in ClinVar: Feb 17, 2020 Last updated: Jan 07, 2023	Publications: PubMed (1) PubMed: 31131967 Comment: IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on … (more) IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 5.98E-08 (less)
Benign (Apr 21, 2016)	criteria provided, single submitter (ACMG Guidelines, 2015) Method: clinical testing	Breast-ovarian cancer, familial, susceptibility to, 1 Affected status: yes Allele origin: germline	Michigan Medical Genetics Laboratories, University of Michigan Accession: SCV000267717.1 First in ClinVar: May 06, 2016 Last updated: May 06, 2016	Tissue: Blood
Likely benign (Mar 07, 2016)	criteria provided, single submitter (ACMG Guidelines, 2015) Method: clinical testing	Hereditary cancer-predisposing syndrome Affected status: unknown Allele origin: germline	Color Diagnostics, LLC DBA Color Health Accession: SCV000537480.1 First in ClinVar: Mar 25, 2017 Last updated: Mar 25, 2017
Likely benign (May 28, 2019)	criteria provided, single submitter (Mendelics Assertion Criteria 2017) Method: clinical testing	Breast-ovarian cancer, familial, susceptibility to, 1 Affected status: unknown Allele origin: unknown	Mendelics Accession: SCV001140491.1 First in ClinVar: Jan 13, 2020 Last updated: Jan 13, 2020
Likely benign (Sep 15, 2021)	criteria provided, single submitter (Sema4 Curation Guidelines) Method: curation	Hereditary cancer-predisposing syndrome Affected status: unknown Allele origin: germline	Sema4, Sema4 Accession: SCV002537808.1 First in ClinVar: Jun 24, 2022 Last updated: Jun 24, 2022
Uncertain significance (Dec 10, 2015)	criteria provided, single submitter (Counsyl Autosomal Dominant Disease Classification criteria (2015)) Method: clinical testing	Breast-ovarian cancer, familial, susceptibility to, 1 Affected status: unknown Allele origin: unknown	Counsyl Accession: SCV000487958.2 First in ClinVar: May 06, 2016 Last updated: Dec 24, 2022	Publications: PubMed (5) PubMed: 24916970‚ 24667779‚ 22505045‚ 16267036‚ 17011978
Benign (Jan 04, 2024)	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015)) Method: clinical testing	Hereditary breast ovarian cancer syndrome Affected status: unknown Allele origin: germline	Labcorp Genetics (formerly Invitae), Labcorp Accession: SCV000259518.10 First in ClinVar: Jan 31, 2016 Last updated: Feb 14, 2024
Benign (Nov 13, 2017)	criteria provided, single submitter (LabCorp Variant Classification Summary - May 2015) Method: clinical testing	not specified Affected status: unknown Allele origin: germline	Women's Health and Genetics/Laboratory Corporation of America, LabCorp Accession: SCV000918720.1 First in ClinVar: Jun 02, 2019 Last updated: Jun 02, 2019	Publications: PubMed (7) PubMed: 16267036‚ 24916970‚ 24667779‚ 26247049‚ 17011978‚ 22505045‚ 10882858 Comment: Variant summary: The BRCA1 c.5074+6C>G variant involves the alteration of a non-conserved intronic nucleotide. MutationTaster predicts a benign outcome for this variant. 4/5 splice prediction … (more) Variant summary: The BRCA1 c.5074+6C>G variant involves the alteration of a non-conserved intronic nucleotide. MutationTaster predicts a benign outcome for this variant. 4/5 splice prediction tools predict no significant impact on normal splicing. Functional studies confirmed that this variant has no effect on splicing (Bonatti_2006, Houdayer_2011, Steffensen_2014). This variant was found in 16/276994 control chromosomes (gnomAD) at a frequency of 0.0000578, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). This variant has been reported in multiple HBOC patients in literature without cosegregation and co-occurrence evidence. In a clinical database (UMD), this variant is reported to co-occur with two deleterious variants in BRCA1 (c.4327C>T (p.Arg1443X) and c.1088delA (p.Asn363IlefsX11)), strongly supporting a benign outcome. In addition, multiple clinical diagnostic laboratories/reputable databases have classified this variant as benign/likely benign. Taken together, this variant is classified as benign. (less)
Benign (Mar 03, 2015)	criteria provided, single submitter (GeneDx Variant Classification Process June 2021) Method: clinical testing	Not Provided Affected status: yes Allele origin: germline	GeneDx Accession: SCV001891516.1 First in ClinVar: Sep 19, 2021 Last updated: Sep 19, 2021	Comment: This variant is associated with the following publications: (PMID: 30209399)
Benign (Jan 18, 2021)	criteria provided, single submitter (Quest Diagnostics criteria) Method: clinical testing	not specified Affected status: unknown Allele origin: unknown	Quest Diagnostics Nichols Institute San Juan Capistrano Accession: SCV001470006.3 First in ClinVar: Jan 26, 2021 Last updated: Dec 31, 2022	Publications: PubMed (10) PubMed: 30209399‚ 31131967‚ 16267036‚ 10882858‚ 31343793‚ 26247049‚ 24916970‚ 17011978‚ 22505045‚ 24667779
Benign (Aug 15, 2023)	criteria provided, single submitter (ACMG Guidelines, 2015) Method: clinical testing	not specified Affected status: unknown Allele origin: germline	Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital Accession: SCV002550957.4 First in ClinVar: Jul 30, 2022 Last updated: Aug 18, 2023
Likely Benign (Dec 13, 2023)	criteria provided, single submitter (ACMG Guidelines, 2015) Method: clinical testing	Breast-ovarian cancer, familial, susceptibility to, 1 (Autosomal dominant inheritance) Affected status: unknown Allele origin: germline	All of Us Research Program, National Institutes of Health Accession: SCV004815201.1 First in ClinVar: Apr 20, 2024 Last updated: Apr 20, 2024 Comment: This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of … (more) This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of variant classification. Additional details can be found in publication PMID: 35346344, PMCID: PMC8962531 (less)	Number of individuals with the variant: 13
Likely benign (Mar 01, 2024)	criteria provided, single submitter (CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2) Method: clinical testing	not provided Affected status: yes Allele origin: germline	CeGaT Center for Human Genetics Tuebingen Accession: SCV004811492.7 First in ClinVar: Apr 15, 2024 Last updated: Oct 20, 2024	Comment: BRCA1: BP4 Number of individuals with the variant: 1
Uncertain significance (May 29, 2002)	no assertion criteria provided Method: clinical testing	Breast-ovarian cancer, familial 1 Affected status: yes Allele origin: germline	Breast Cancer Information Core (BIC) (BRCA1) Accession: SCV000145292.1 First in ClinVar: Apr 01, 2014 Last updated: Apr 01, 2014	Number of individuals with the variant: 2 Ethnicity/Population group: Western European
Benign (Feb 04, 2009)	no assertion criteria provided Method: clinical testing	Breast-ovarian cancer, familial 1 Affected status: not provided Allele origin: germline	Sharing Clinical Reports Project (SCRP) Accession: SCV000108950.2 First in ClinVar: Dec 23, 2013 Last updated: Sep 27, 2014
Likely benign (Oct 07, 2013)	no assertion criteria provided Method: clinical testing	Breast and/or ovarian cancer Affected status: unknown Allele origin: germline	Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research Study: The Canadian Open Genetics Repository (COGR) Accession: SCV000863698.1 First in ClinVar: Dec 24, 2018 Last updated: Dec 24, 2018
Likely benign (-)	no assertion criteria provided Method: clinical testing	not provided Affected status: yes Allele origin: unknown	Department of Pathology and Laboratory Medicine, Sinai Health System Additional submitter: Franklin by Genoox Study: The Canadian Open Genetics Repository (COGR) Accession: SCV000591569.2 First in ClinVar: Aug 28, 2017 Last updated: Apr 13, 2021	Comment: The BRCA1, c.5074+6C>G variant was identified in 1 of 552 proband chromosomes (frequency: 0.002) from individuals or families with breast cancer (Bonatti 2006). The variant … (more) The BRCA1, c.5074+6C>G variant was identified in 1 of 552 proband chromosomes (frequency: 0.002) from individuals or families with breast cancer (Bonatti 2006). The variant was also identified in dbSNP (ID: rs80358032), NHLBI Exome Sequencing Project (Exome Variant Server), Exome Aggregation Consortium (ExAC) database, LOVD, the ClinVar database (classified as a benign variant by the Sharing Clinical Reports Project, derived from Myriad reports; classified as an uncertain significance by BIC), GeneInsight VariantWire database (2X, classified as IARC 3 and Benign by clinical laboratories), the BIC database (2X with unknown clinical importance) and UMD (6X as a likely neutral variant). In UMD the variant was identified with a co-occurring pathogenic BRCA1 variant (c.4327C>T (p.Arg1443X)), increasing the likelihood that the c.5074+6C>G variant does not have clinical significance. This variant was identified in the Exome Variant Server project in 1 of 8600 European American alleles, the Exome Aggregation Consortium (ExAC) database (released Oct 20th, 2014) in 7 of 66484 chromosomes (frequency: 0.00001) from a population of European (Non-Finnish) individuals, although this low number of observations and low frequency is not substantive enough to determine the prevalence of the variant in the general population and its relationship to disease. The c.5074+6C>G variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. However, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. An RNA-based study by Bonatti (2006) found that the variant showed the same pattern in RT-PCR product as normal controls, suggesting that this variant expresses a normal mRNA transcript which would likely be translated into a wild-type protein. However, functional study by Steffensen (2014) identified minor increase in skipping of exon 17; minor increase in the transcripts lacking exon 17 compared with the wild type and classifies this variant as a VUS. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as predicted benign. (less)
Likely benign (-)	no assertion criteria provided Method: clinical testing	not provided Affected status: yes Allele origin: germline	Genome Diagnostics Laboratory, University Medical Center Utrecht Additional submitter: Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen Study: VKGL Data-share Consensus Accession: SCV001930809.1 First in ClinVar: Sep 24, 2021 Last updated: Sep 24, 2021
Likely benign (Dec 28, 2016)	no assertion criteria provided Method: clinical testing	not provided Affected status: unknown Allele origin: unknown	Mayo Clinic Laboratories, Mayo Clinic Accession: SCV000778734.1 First in ClinVar: Jun 25, 2018 Last updated: Jun 25, 2018
Benign (Mar 01, 2019)	no assertion criteria provided Method: research	Hereditary breast and ovarian cancer syndrome Affected status: yes Allele origin: germline	Hereditary Cancer Genetics group, Vall d'Hebron Institute of Oncology Accession: SCV000916355.1 First in ClinVar: Sep 01, 2019 Last updated: Sep 01, 2019	Publications: PubMed (1) PubMed: 30472649 Sex: female
Likely benign (-)	no assertion criteria provided Method: clinical testing	not provided Affected status: yes Allele origin: germline	Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute Additional submitter: Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen Study: VKGL Data-share Consensus Accession: SCV001906317.1 First in ClinVar: Sep 24, 2021 Last updated: Sep 24, 2021
Benign (-)	no assertion criteria provided Method: clinical testing	not specified Affected status: yes Allele origin: germline	Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ Additional submitter: Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen Study: VKGL Data-share Consensus Accession: SCV001956818.1 First in ClinVar: Oct 02, 2021 Last updated: Oct 02, 2021
Benign (-)	no assertion criteria provided Method: clinical testing	not specified Affected status: yes Allele origin: germline	Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center Additional submitter: Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen Study: VKGL Data-share Consensus Accession: SCV001969002.1 First in ClinVar: Oct 07, 2021 Last updated: Oct 07, 2021
Benign (Mar 02, 2020)	no assertion criteria provided Method: clinical testing	Breast-ovarian cancer, familial, susceptibility to, 1 Affected status: yes Allele origin: germline	BRCAlab, Lund University Accession: SCV004243953.1 First in ClinVar: Feb 14, 2024 Last updated: Feb 14, 2024
not provided (-)	no classification provided Method: in vitro	Breast-ovarian cancer, familial 1 Affected status: not applicable Allele origin: not applicable	Brotman Baty Institute, University of Washington Accession: SCV001243471.1 First in ClinVar: Apr 18, 2020 Last updated: Apr 18, 2020	Publications: PubMed (1) PubMed: 30209399 Other databases https://sge.gs.washington.edu/BR… https://sge.gs.washington.edu/BRCA1/ Method: saturation genome editing in haploid cells Result: FUNCTIONAL:-0.356637438283172
click to load more click to collapse

Comment:

Variant summary: The BRCA1 c.5074+6C>G variant involves the alteration of a non-conserved intronic nucleotide. MutationTaster predicts a benign outcome for this variant. 4/5 splice prediction tools predict no significant impact on normal splicing. Functional studies confirmed that this variant has no effect on splicing (Bonatti_2006, Houdayer_2011, Steffensen_2014). This variant was found in 16/276994 control chromosomes (gnomAD) at a frequency of 0.0000578, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). This variant has been reported in multiple HBOC patients in literature without cosegregation and co-occurrence evidence. In a clinical database (UMD), this variant is reported to co-occur with two deleterious variants in BRCA1 (c.4327C>T (p.Arg1443X) and c.1088delA (p.Asn363IlefsX11)), strongly supporting a benign outcome. In addition, multiple clinical diagnostic laboratories/reputable databases have classified this variant as benign/likely benign. Taken together, this variant is classified as benign.

Comment:

The BRCA1, c.5074+6C>G variant was identified in 1 of 552 proband chromosomes (frequency: 0.002) from individuals or families with breast cancer (Bonatti 2006). The variant was also identified in dbSNP (ID: rs80358032), NHLBI Exome Sequencing Project (Exome Variant Server), Exome Aggregation Consortium (ExAC) database, LOVD, the ClinVar database (classified as a benign variant by the Sharing Clinical Reports Project, derived from Myriad reports; classified as an uncertain significance by BIC), GeneInsight VariantWire database (2X, classified as IARC 3 and Benign by clinical laboratories), the BIC database (2X with unknown clinical importance) and UMD (6X as a likely neutral variant). In UMD the variant was identified with a co-occurring pathogenic BRCA1 variant (c.4327C>T (p.Arg1443X)), increasing the likelihood that the c.5074+6C>G variant does not have clinical significance. This variant was identified in the Exome Variant Server project in 1 of 8600 European American alleles, the Exome Aggregation Consortium (ExAC) database (released Oct 20th, 2014) in 7 of 66484 chromosomes (frequency: 0.00001) from a population of European (Non-Finnish) individuals, although this low number of observations and low frequency is not substantive enough to determine the prevalence of the variant in the general population and its relationship to disease. The c.5074+6C>G variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. However, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. An RNA-based study by Bonatti (2006) found that the variant showed the same pattern in RT-PCR product as normal controls, suggesting that this variant expresses a normal mRNA transcript which would likely be translated into a wild-type protein. However, functional study by Steffensen (2014) identified minor increase in skipping of exon 17; minor increase in the transcripts lacking exon 17 compared with the wild type and classifies this variant as a VUS. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as predicted benign.

Germline Functional Evidence

Functional Help The functional consequence of the variant, based on experimental evidence and provided by the submitter. consequence	Method Help A brief description of the method used to determine the functional consequence of the variant. A citation for the method is included, when provided by the submitter.	Result Help A brief description of the result of this method for this variant.	Submitter Help The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar.	More information Help This column includes more information supporting functional evidence for the germline classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter.
functionally_normal (SO:0002219)	saturation genome editing in haploid cells Method citation(s): PubMed(1)	FUNCTIONAL:-0.356637438283172	Brotman Baty Institute, University of Washington Accession: SCV001243471.1	Publications PubMed (1) Other databases https://sge.gs.washington.edu/BR… Comment: The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5074+6C>G, a SPLICE REGION variant, produced a function score of -0.36, corresponding to a functional classification of … (more) The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5074+6C>G, a SPLICE REGION variant, produced a function score of -0.36, corresponding to a functional classification of FUNCTIONAL. SGE function score ranges for classification are as follows: â€˜functionalâ€™, score > -0.748; â€˜intermediateâ€™, -0.748 > score > -1.328; â€˜non-functionalâ€™, score < -1.328. The median synonymous SNV scored 0.0 and the median nonsense SNV scored -2.12. (less)

Comment:

Citations for germline classification of this variant

Title	Author	Journal	Year	Link
Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.	Montalban G	Human mutation	2019	PMID: 31343793
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.	Parsons MT	Human mutation	2019	PMID: 31131967
Accurate classification of BRCA1 variants with saturation genome editing.	Findlay GM	Nature	2018	PMID: 30209399
Splicing analysis for exonic and intronic mismatch repair gene variants associated with Lynch syndrome confirms high concordance between minigene assays and patient RNA analyses.	van der Klift HM	Molecular genetics & genomic medicine	2015	PMID: 26247049
The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry.	Peixoto A	Clinical genetics	2015	PMID: 24916970
Functional characterization of BRCA1 gene variants by mini-gene splicing assay.	Steffensen AY	European journal of human genetics : EJHG	2014	PMID: 24667779
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants.	Houdayer C	Human mutation	2012	PMID: 22505045
RNA-based analysis of BRCA1 and BRCA2 gene alterations.	Bonatti F	Cancer genetics and cytogenetics	2006	PMID: 17011978
Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.	Judkins T	Cancer research	2005	PMID: 16267036
Incidence of BRCA1/2 germ line alterations in a high risk cohort participating in a phase II chemoprevention trial.	Klemp J	European journal of cancer (Oxford, England : 1990)	2000	PMID: 10882858
https://sge.gs.washington.edu/BRCA1/	-	-	-	-
click to load more click to collapse

Text-mined citations for rs80358032 ...

These citations are identified by LitVar using the rs number, so they may include citations for more than one variant at this location. Please review the LitVar results carefully for your variant of interest.

Record last updated Oct 27, 2024

ClinVar Genomic variation as it relates to human health

NM_007294.4(BRCA1):c.5074+6C>G

Variant Details

Genes

Conditions - Germline

Submissions - Germline

Germline Functional Evidence

Citations for germline classification of this variant

Text-mined citations for rs80358032 ...